However, the available DNA samples of different quantity and quality, the various types of mutations, and the emergence of new targeted cancer therapies all require the development of innovative diagnostic pipelines for BRCA1/2 that integrate the multiple needs and offer more reliable methods for detecting hereditary and somatic mutations of the BRCA genes. The gene discussed is BRCA1; the disease is cancer.